Group 1 - The company has issued a voluntary performance forecast for the period from January 1, 2025, to December 31, 2025, expecting a positive net profit attributable to shareholders and a positive net profit after deducting non-recurring gains and losses, both showing an upward trend [1] - The preliminary data for the performance forecast has been calculated by the company's finance department and has not yet been audited by an external auditor. There are no discrepancies between the company and the auditing firm regarding this performance forecast [1] - The increase in performance is attributed to the rapid development of the company's centralized operation of medical consumables (SPD) business, which has a high gross profit margin, enhancing the overall profitability of the company. Additionally, the company has optimized its financial structure, reducing interest-bearing debt year-on-year and lowering financing costs through negotiations with financial institutions, positively impacting net profit [1]
上海建发致新医疗科技集团股份有限公司 2025年度业绩预告